CAPR
Company Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 22.27M | 25.18M | 2.55M | 244,898 | 310,250 | 1.01M | 1.67M | 2.67M | 3.19M | 3.78M | 4.17M |
| Net Income | (105.04M) | (40.47M) | (22.29M) | (29.02M) | (20.02M) | (13.66M) | (7.64M) | (15.19M) | 2.43M | (18.81M) | (12.86M) | (6.22M) |
| EPS | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 |
| Free Cash Flow | (72.72B) | (41.53M) | (27.64M) | 1.56M | (18.01M) | (10.60M) | (6.82M) | (14.18M) | (14.26M) | (16.00M) | N/A | N/A |
| FCF / Share | -1564.51 | -1.18 | -1.03 | 0.06 | -0.78 | -0.68 | -1.84 | -4.83 | -6.15 | -8.62 | N/A | N/A |
| Operating CF | (69.81B) | (40.00M) | (25.60M) | 4.92M | (16.81M) | (10.05M) | (6.82M) | (13.86M) | (14.23M) | (15.80M) | N/A | N/A |
| Total Assets | 355.95M | 170.48M | 58.73M | 50.09M | 41.33M | 34.62M | 11.11M | 9.25M | 16.27M | 18.75M | N/A | N/A |
| Total Debt | 20.94M | 1.45M | 2.24M | 2.56M | 2.87M | 318,160 | 0 | 0 | 0 | 13.91M | N/A | N/A |
| Cash & Equiv | 287.85M | 11.29M | 14.69M | 9.60M | 34.89M | 32.67M | 3.90M | 4.26M | 6.14M | 3.20M | N/A | N/A |
| Book Value | 305.79M | 145.46M | 22.60M | 11.79M | 31.37M | 28.20M | 6.84M | 4.62M | 11.23M | (4.00M) | N/A | N/A |
| Return on Equity | -0.34 | -0.28 | -0.99 | -2.46 | -0.64 | -0.48 | -1.12 | -3.29 | 0.22 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 11.13M | 2.26M | 3.97M | 4.91M | 12.09M | 6.19M | 3.92M |
| Net Income | (33.94M) | (30.17M) | (24.57M) | (25.91M) | (24.39M) | (7.12M) | (12.56M) | (11.00M) | (9.79M) | (762,089) | (6.39M) | (7.37M) |
| EPS | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 | -0.38 | -0.35 | -0.31 | -0.02 | -0.25 | -0.29 |
| Free Cash Flow | (40.00M) | (28.69M) | (23.70M) | (21.57M) | (7.57M) | (15.53M) | (11.70M) | (12.37M) | (1.93M) | (12.32M) | (9.43M) | (9.65M) |
| FCF / Share | -0.70 | -0.59 | -0.52 | -0.47 | -0.17 | -0.44 | -0.35 | -0.39 | -0.06 | -0.46 | -0.37 | -0.38 |
| Operating CF | (29.25M) | (23.57M) | (19.69M) | (20.12M) | (6.43M) | (14.80M) | (11.64M) | (12.29M) | (1.27M) | (11.59M) | (8.79M) | (9.42M) |
| Total Assets | 326.28M | 355.95M | 126.44M | 133.57M | 153.77M | 170.48M | 92.95M | 38.28M | 49.44M | 58.73M | 37.15M | 46.01M |
| Total Debt | 21.12M | 20.94M | 14.54M | 1.04M | 1.25M | 1.45M | 1.65M | 1.84M | 2.02M | 2.24M | 2.41M | 2.23M |
| Cash & Equiv | 105.42M | 287.85M | 19.51M | 23.24M | 28.79M | 11.29M | 68.38M | 10.69M | 6.21M | 14.69M | 8.98M | 9.84M |
| Book Value | 278.70M | 305.79M | 83.87M | 104.98M | 127.65M | 145.46M | 68.26M | 11.50M | 18.43M | 22.60M | (1.79M) | 2.73M |
| Return on Equity | -0.12 | -0.10 | -0.29 | -0.25 | -0.19 | -0.05 | -0.18 | -0.96 | -0.53 | -0.03 | N/A | -2.70 |
